Improved expression by cytomegalovirus promoter/enhancer and behavior of vascular endothelial growth factor gene after myocardial injection of naked DNA

Experimental and Molecular Medicine

Volumn 34, Issue 4, 2002, Pages 278-284

  Jeong, Jin Ok ^a   Byun, Jonghoe ^b   Jeon, Eun Seok ^b   Gwon, Hyeon Cheol ^b   Lim, Young Shin ^b   Park, Jangwon ^b   Yeo, Seon Ju ^b   Lee, Young Joo ^c   Kim, Sunyoung ^d   Kim, Duk Kyung ^b  

^a Chungnam National University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Sejong University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Gene therapy; Heart; Naked DNA; VEGF

Indexed keywords

NAKED DNA; PLASMID DNA; PLASMID VECTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS; ENHANCER REGION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HEART MUSCLE; IMMEDIATE EARLY GENE; MALE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; RAT;

ANIMALIA; CYTOMEGALOVIRUS; FELIS CATUS; HUMAN HERPESVIRUS 5;

EID: 0037201447     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2002.39     Document Type: Article

References (26)

1. Buttrick PM, Kass A, Kitsis RN, Kaplan ML, Leinwand LA. Behavior of genes directly injected into the rat heart in vivo. Circ Res 1992;70:193-8
2. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard JC, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D'Amore PA, Shima DT. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999;5:495-502
3. Chapman BS, Thayer RM, Vincent KA, Haigwood NL. Effect of intron A from human cytomegalovirus (Towne) immediateearly gene on heterologous expression in mammalian cells. Nucleic Acids Res 1991;19:3979-86
4. Darren CW, Tana R, Manjunatha Kinia, Seetharama DS, Joisb Derrick KF, Lima. Lixia Xina and Ruowen Gea. A small peptide derived from FIt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett 2001;494:150-6
5. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-32
6. Heller R, Jaroszeski M, Atkin A, Moradpour D, Gilbert R, Wands J, Nicolau C. In vivo gene electroinjection and expression in rat liver. FEBS Lett 1996;389:225-8
7. Isner JM, Losordo DW. Therapeutic angiogenesis for heart failure. Nat Med 1999;5:491-2
8. Kass-Eisler A, Leinwand LA. DNA- and adenovirus-mediated gene transfer into cardiac muscle. Methods Cell Biol 1997;52:423-37
9. Kay MA, Liu D, Hoogerbrugge PM. Gene therapy. Proc Natl Acad Sci USA 1997;94:12744-6
10. Kitsis RN, Buttrick PM, McNally EM, Kaplan ML, Leinwand LA. Hormonal modulation of a gene injected into rat heart in vivo. Proc Natl Acad Sci USA 1991;88:4138-42
11. Lee YJ, Park EJ, Yu SS, Kim DK, Kim S. Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: Implication for gene therapy of ischemic diseases. Biochem Biophys Res Commun 2000;272:230-5
12. Li K, Welikson RE, Vikstrom KL, Leinwand LA. Direct gene transfer into the mouse heart. J Mol Cell Cardiol 1997;29:1499-504
13. Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation 1990;82:2217-21
14. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-4
15. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22
16. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-26
17. Petitclerc D, Attal J, Theron MC, Bearzotti M, Bolifraud P, Kann G, Stinnakre MG, Pointu H, Puissant C, Houdebine LM. The effect of various introns and transcription terminators on the efficiency of expression vectors in various cultured cell lines and in the mammary gland of transgenic mice. J Biotechnol 1995;40:169-78
18. Rosengart TK, Patel SR, Crystal RG. Therapeutic angiogenesis: Protein and gene therapy delivery strategies. J Cardiovasc Risk 1999;6:29-40
19. Simari RD, Yang Z, Ling X, Stephan D, Perkins ND, Nabel GJ, Nabel EG. Requirements for enhanced transgene expression by untranslated sequences from the human cytomegalovirus immediate-early gene. Mol Med 1998;4:700-6
20. Slobin LI. The role of eucaryotic factor Tu in protein synthesis. The measurement of the elongation factor Tu content of rabbit reticulocytes and other mammalian cells by a sensitive radioimmunoassay. Eur J Biochem 1980;110:555-63
21. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999;68:830-7
22. Thomson JF, Hayes LS, Lloyd DB. Modulation of firefly luciferase, stability and impact on studies of gene regulation. Gene 1991;103:171-7
23. Verma IM, Somia N. Gene therapy - Promises, problems, and prospects. Nature 1997;389:239-42
24. von Harsdorf R, Schott RJ, Shen YT, Vatner SF, Mahdavi V, Nadal-Ginard B. Gene injection into canine myocardium as a useful model for studying gene expression in the heart of large mammals. Circ Res 1993;72:688-95
25. Wakabayashi-Ito N, Nagata S. Characterization of the regulatory elements in the promoter of the human elongation factor-1 alpha gene. J Biol Chem 1994;269:29831-7
26. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000;355:213-22